CTBP1 and cardiovascular disorder: Indeed, several preclinical and observational studies have suggested the possibility that β-ARs blockers, drugs originally intended for the treatment of cardiovascular disease, may provide new therapeutic opportunities for the control of cancer progression, including that of melanoma, breast and prostate cancers [48].